Checkpoint Therapeutics, Inc. (CKPT)
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
$109.02M
Mr. James F. Oliviero III, C.F.A., CFA
14.00
Waltham, MA
Nov 02, 2016
-1.44
$-1.71
0.23
0.26
-54,444.87%
-2.17
-0.02
-5.84
1,431.81
0.26
-748.98%
292.43%
Similar stocks (14)
Instil Bio, Inc.
TIL
Kodiak Sciences Inc.
KOD
Assembly Biosciences, Inc.
ASMB
CytomX Therapeutics, Inc.
CTMX
Spero Therapeutics, Inc.
SPRO
Aileron Therapeutics, Inc.
ALRN
Reviva Pharmaceuticals Holdings, Inc.
RVPH
Fortress Biotech, Inc.
FBIO
Fortress Biotech, Inc.
FBIOP
Lumos Pharma, Inc.
LUMO
Cue Biopharma, Inc.
CUE
Pieris Pharmaceuticals, Inc.
PIRS
Mustang Bio, Inc.
MBIO
Avenue Therapeutics, Inc.
ATXI
ETF Exposure (6)
iShares Micro-Cap ETF
IWC
0.01849%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (14)
Instil Bio, Inc.
TIL
Kodiak Sciences Inc.
KOD
Assembly Biosciences, Inc.
ASMB
CytomX Therapeutics, Inc.
CTMX
Spero Therapeutics, Inc.
SPRO
Aileron Therapeutics, Inc.
ALRN
Reviva Pharmaceuticals Holdings, Inc.
RVPH
Fortress Biotech, Inc.
FBIO
Fortress Biotech, Inc.
FBIOP
Lumos Pharma, Inc.
LUMO
Cue Biopharma, Inc.
CUE
Pieris Pharmaceuticals, Inc.
PIRS
Mustang Bio, Inc.
MBIO
Avenue Therapeutics, Inc.
ATXI
ETF Exposure (6)
iShares Micro-Cap ETF
IWC
0.01849%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%